Clinical Policy Title: AfirmaTM gene expression classifier for indeterminate thyroid nodules
ثبت نشده
چکیده
ABOUT THIS POLICY: AmeriHealth Caritas Northeast has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Northeast’s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peerreviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any stateor plan-specific definition of “medically necessary,” and the specific facts of the particular situation are considered by AmeriHealth Caritas Northeast when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Northeast’s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Northeast’s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Northeast will update its clinical policies as necessary. AmeriHealth Caritas Northeast’s clinical policies are not guarantees of payment.
منابع مشابه
Clinical Policy Title: Genetic tests for Duchenne muscular dystrophy
CP# 02.01.01 Maternal genetic testing CP# 02.01.02 Genetic testing for breast and ovarian cancer CP# 02.01.03 Array comparative genomic hybridization testing CP# 02.01.13 Pharmacogenetic testing for warfarin CP# 02.01.07 Genetic testing for cystic fibrosis CP# 02.01.08 Familial polyposis gene testing CP# 02.01.10 COLARIS® test for Lynch syndrome CP# 02.01.11 AfirmaTM gene expression classifier ...
متن کاملClinical Policy Title: AfirmaTM gene expression classifier for indeterminate thyroid nodules
ABOUT THIS POLICY: Prestige Health Choice has developed clinical policies to assist with making coverage determinations. Prestige Health Choice’s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and p...
متن کاملThyroid Nodules with Indeterminate Cytology
To the Editor: Alexander et al. (Aug. 23 issue)1 report findings from a prospective, multicenter gene-expression classifier validation study that raises several questions. For the 265 indeterminate fine-needle aspirates they tested, the geneexpression classifier had a sensitivity of 92%, a specificity of 52%, a positive predictive value of 47%, and a negative predictive value of 93%. Why the ob...
متن کاملMolecular Markers in Fine Needle Aspirates of the Thyroid
When Policy Topic is covered The use of the Afirma Gene Expression Classifier in fine needle aspirates of the thyroid that are cytologically considered to be indeterminate (follicular lesion of undetermined significance or follicular neoplasm) may be considered medically necessary in patients who have the following characteristics: Thyroid nodules without strong clinical or radiologic finding...
متن کاملPreoperative diagnosis of benign thyroid nodules with indeterminate cytology.
BACKGROUND Approximately 15 to 30% of thyroid nodules evaluated by means of fine-needle aspiration are not clearly benign or malignant. Patients with cytologically indeterminate nodules are often referred for diagnostic surgery, though most of these nodules prove to be benign. A novel diagnostic test that measures the expression of 167 genes has shown promise in improving preoperative risk asse...
متن کامل